Cancer treatment – Parentraide Cancer http://parentraide-cancer.org/ Sat, 02 Jul 2022 11:31:38 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://parentraide-cancer.org/wp-content/uploads/2021/06/icon.png Cancer treatment – Parentraide Cancer http://parentraide-cancer.org/ 32 32 Cleveland Clinic appoints oncologist to head Taussig Cancer Institute https://parentraide-cancer.org/cleveland-clinic-appoints-oncologist-to-head-taussig-cancer-institute/ Sat, 02 Jul 2022 11:31:38 +0000 https://parentraide-cancer.org/cleveland-clinic-appoints-oncologist-to-head-taussig-cancer-institute/ ADD A SUBJECT TO EMAIL ALERTS Receive an email when new articles are published on Please provide your email address to receive an email when new articles are published on . ” data-action=”subscribe”> Subscribe We have not been able to process your request. Please try again later. If you continue to […]]]>


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Alex A. Adjei, MD, PhD, was named president of the Cleveland Clinic Taussig Cancer Institute.

Adjei previously served as an oncology consultant, professor of oncology, and professor of pharmacology at Mayo Clinic and Mayo Clinic College of Medicine and Science in Rochester, Minnesota.

While there, he co-directed the therapeutic development program at Mayo Clinic Cancer Center. He also oversaw oncology drug development, as well as lung cancer research and treatment at multiple Mayo Clinic sites.

Adjei Alex

Alex A. Adjei

“It is an honor to welcome Dr. Adjei as the head of our Taussig Cancer Institute”, Beri Ridgeway, MD, chief of staff at the Cleveland Clinic, said in a press release. “His clinical expertise, extensive oncology research accomplishments and extensive leadership experience will benefit our institute and advance patient care. »

Adjei’s research has focused on experimental therapeutics, regulatory science and clinical drug development, as well as health disparities, global oncology, new drug treatments for lung cancer and the effects of drug toxicity.

“Cancer is one of the most harrowing diseases that afflict humans,” Adjei said in the statement. “Fortunately, thanks to recent scientific advances, we are making progress towards understanding, preventing and treating all forms of cancer. I am truly honored and thrilled to have the opportunity to work with this talented team of professionals and help position the Cleveland Clinic at the forefront of cancer care.

Abraham James

Jacques Abraham

Adjei previously served as chair of cancer medicine, senior vice president of clinical research, chair of the department of medicine, and professor of oncology at Roswell Park Comprehensive Cancer Center.

James Abraham, M.D – who served as interim president of the Taussig Cancer Institute since May 2021 – will continue to serve as chair of the Department of Hematology and Medical Oncology at the Taussig Cancer Institute.

]]>
Nicola Sturgeon defends missed cancer treatment goals https://parentraide-cancer.org/nicola-sturgeon-defends-missed-cancer-treatment-goals/ Thu, 30 Jun 2022 12:40:23 +0000 https://parentraide-cancer.org/nicola-sturgeon-defends-missed-cancer-treatment-goals/ The Prime Minister has defended her government’s record on cancer wait times after Labor’s Anas Sarwar pointed out that the target of 62 days from receiving the referral for treatment had been missed more than 3,000 times in the last year. Nicola Sturgeon said the 31-day target from decision to treat to first treatment was […]]]>

The Prime Minister has defended her government’s record on cancer wait times after Labor’s Anas Sarwar pointed out that the target of 62 days from receiving the referral for treatment had been missed more than 3,000 times in the last year.

Nicola Sturgeon said the 31-day target from decision to treat to first treatment was met, while the NHS had also increased the number of patients seen overall.

She added: “Once the decision to treat is made, patients wait an average of four days to start treatment.”

But Sarwar pointed out that more than 78,000 patients were waiting more than six weeks for diagnostic tests. This is a 76% increase from a year ago, he added.

Sarwar accused the Scottish government of putting independence ambitions ahead of efforts to tackle cancer waiting times.

He said: “The recovery hasn’t even started yet. In fact, things got worse. Instead, we’ve gone back to divisive Nicola Sturgeon, who now spends seven days a week, sometimes what feels like 24 hours a day, focusing on what matters to him: breaking up our country and dividing our people. .

The Prime Minister pointed out that there had been ‘new waves’ of the Covid pandemic over the past year which had had an impact on waiting times.

She also said NHS Scotland had higher staff numbers and better pay offers than was the case in England.

She added: “Coming to the political point of Anas Sarwar, here is the point: he wants to support the conservatives. I want to free Scotland from the Tories.

“The worst thing that can happen to our NHS is to continue to see Conservative governments cut the budget of this government and this parliament. This is why having the powers of independence is good for the country, including our national health service.

]]>
It is absolutely necessary to check the overall price of Parl panel for cancer treatment https://parentraide-cancer.org/it-is-absolutely-necessary-to-check-the-overall-price-of-parl-panel-for-cancer-treatment/ Tue, 28 Jun 2022 03:32:41 +0000 https://parentraide-cancer.org/it-is-absolutely-necessary-to-check-the-overall-price-of-parl-panel-for-cancer-treatment/ Stressing the need to make cancer treatment affordable, a parliamentary panel on Monday suggested senior government officials consider waiving the GST on cancer drugs and take strict measures to check drug prices and drug prices. radiation therapy, sources said. The panel also suggested that cancer should be a “notifiable disease” so that its “true burden” […]]]>

Stressing the need to make cancer treatment affordable, a parliamentary panel on Monday suggested senior government officials consider waiving the GST on cancer drugs and take strict measures to check drug prices and drug prices. radiation therapy, sources said.

The panel also suggested that cancer should be a “notifiable disease” so that its “true burden” on the country can be determined and action taken to provide help to patients. A reportable disease must, by law, be reported to government authorities. Collecting information allows authorities to monitor the disease.

Stressing that cancer treatment is “very expensive” in the country, panel members told Health Ministry officials that there was a strong need to check the overall price of cancer treatment, sources said.

Senior ministry officials, including Secretary Rajesh Bhushan, testified before the House Health and Family Welfare Committee on Monday to discuss “affordability of cancer treatment“.

Discussing the structure of the GST on drugs used for the treatment of cancer, panel members from various parties said the government should explore the possibility of exempting the GST on these drugs to reduce their prices and make the more affordable treatment, sources said.

At the same time, the government should take strict measures to control the prices of drugs and radiotherapy used for cancer treatment, they said.

Officials informed the panel that the national drug regulatory authority has so far set price ceilings for 86 formulations, streamlined trade margins for 49 drugs, and reduced the MRP (maximum retail price) of drugs used for treatment. cancer treatment up to 90%. .

The government also wants to roll out the HPV vaccine nationwide, which is used for the treatment of cervical cancer, they said, adding that regulatory approval had been granted but that the case is pending. According to various health organizations including the World Health Organization, cancer cases are gradually increasing in India and it is one of the leading causes of death with 7.84 lakh deaths recorded in 2018 and 13.92 lakh cases reported in 2020.

Cancer treatment also includes post-treatment care and rehabilitation.

Nationally, the average total expenditure for cancer care exceeded Rs 1.16 lakh per patient, while in private hospitals, the total cost of cancer care was estimated at over Rs 1.41 lakh and just above Rs 72,000 in public hospitals.

(PTI)


]]>
Teen holding spearfishing event in panama city beach for cancer research https://parentraide-cancer.org/teen-holding-spearfishing-event-in-panama-city-beach-for-cancer-research/ Sun, 26 Jun 2022 12:04:23 +0000 https://parentraide-cancer.org/teen-holding-spearfishing-event-in-panama-city-beach-for-cancer-research/ PANAMA CITY BEACH — Colten White’s medical history has always been complicated, he says. At age 8, he was diagnosed with a common vitamin immune deficiency, and at age 10, he was diagnosed with juvenile idiopathic arthritis. Still, it came as a shock to the Alabama native and part-time resident of Panama City Beach when […]]]>
]]>
Integrating Sequential Immunotherapy into Lung Cancer Treatment Plans https://parentraide-cancer.org/integrating-sequential-immunotherapy-into-lung-cancer-treatment-plans/ Fri, 24 Jun 2022 11:00:59 +0000 https://parentraide-cancer.org/integrating-sequential-immunotherapy-into-lung-cancer-treatment-plans/ June 24, 2022 1 minute watch Source/Disclosures Published by: Source: Healio Interviews Disclosures: Marmarelis reports holding shares and other interests in Bluebird Bio, Gilead Sciences, Johnson & Johnson, Merck, Pfizer and Portola Pharmaceuticals; receive honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda and Targeted Oncology; act as a consultant or […]]]>

June 24, 2022

1 minute watch

Source:

Healio Interviews


Disclosures: Marmarelis reports holding shares and other interests in Bluebird Bio, Gilead Sciences, Johnson & Johnson, Merck, Pfizer and Portola Pharmaceuticals; receive honoraria from AstraZeneca, Blueprint Medicines, Health Advances, Janssen Oncology, Novocure, Takeda and Targeted Oncology; act as a consultant or advisor for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb/Celgene and Ikena Oncology; receive research funding for the Marmarelis institution from AstraZeneca, Lilly and Trizell; receive travel, accommodation and expenses from Boehringer Ingelheim and Novocure; and have another relationship with Novartis.


We have not been able to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

In this video, Melina Marmarelis, MD, highlights results from an unpaired Lung-MAP substudy presented at the ASCO Annual Meeting.

“The idea of ​​sequential immunotherapy is something we’re all grappling with in this era of multiple different immunotherapies being approved in different lines,” said Marmarelis, an assistant professor of medicine at the University of Pennsylvania.

Reference:

  • Reckamp KL, et al. Overall survival from a randomized phase II study of ramucirumab plus pembrolizumab versus standard therapy for advanced non-small cell lung cancer previously treated with immunotherapy: unmatched Lung-MAP substudy S1800A. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

]]>
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™ https://parentraide-cancer.org/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart/ Wed, 22 Jun 2022 20:01:00 +0000 https://parentraide-cancer.org/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart/ JERUSALEM, June 22, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of innovative alpha radiation cancer therapy Alpha DaRT™, today announced that the first patient has been treated in a feasibility study evaluating the Alpha DaRT as neoadjuvant therapy in patients with prostate cancer at the Rambam Health Care Center […]]]>

JERUSALEM, June 22, 2022 /PRNewswire/ — Alpha Tau Medical Ltd. (Nasdaq: DRTS) (“Alpha Tau”), the developer of innovative alpha radiation cancer therapy Alpha DaRT™, today announced that the first patient has been treated in a feasibility study evaluating the Alpha DaRT as neoadjuvant therapy in patients with prostate cancer at the Rambam Health Care Center in Haifa, Israel.

The main objectives of this study are to evaluate the feasibility and safety of intratumoral implantation of the Alpha DaRT source for the treatment of local prostate cancer before surgery. Secondary objectives include assessment of radiological and pathologic objective tumor response rate and changes in quality of life measures. The study involves two separate procedures, with surgical resection of the prostate 50 days after insertion of the Alpha DaRT source, and can enroll up to 10 patients. The surgical resection will be performed at Carmel Medical Center in Haifa, Israel using a da Vinci® surgical robot, and will be led by Dr. Yuval Freifeld and his senior team.

“This is a historic day for Alpha Tau,” said Alpha Tau CEO Uzi Sofer. “Having gained a wealth of experience in treating superficial cancers such as skin, head and neck and breast, we are delighted to have treated the first prostate patient, our first internal organ treatment. Our preclinical data shows that the Alpha DaRT technology may have the potential to treat a very wide range of solid tumor types, and our strategy is to expand our clinical studies to multiple tumor types to assess the full potential of the ‘Alpha DaRT is a promising treatment beyond superficial tumors and is an important step in executing this strategy.’

Alpha Tau CMO Dr. Robert Den noted, “Since the prostate is surgically removed 50 days after Alpha DaRT insertion, the neoadjuvant design of this trial will allow us to analyze the pathological response of tissues to Alpha DaRT. We hope that This will provide very valuable information to our researchers and allow us to compare theoretical and actual cell damage.”

Dr. Tomer Charas, head of the GU radiation therapy unit in the oncology division of the Rambam Health Care Center in Haifa, Israeland principal investigator of the study, said, “We are thrilled to be leading this trial in collaboration with Carmel’s urology team and to be the first to evaluate Alpha DaRT in prostate cancer patients. Based on the results of preclinical studies, it is possible that neoadjuvant treatment with Alpha DaRT may also trigger an immune response, which could help decrease the risk of tumor recurrence. Additionally, a preferable safety profile has been observed to date in treatments for other tumor types.

About Alpha DaRT

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to provide highly potent and conformal alpha irradiation of solid tumors by intratumoral administration of radium-224 impregnated sources. As the radium decays, its short-lived progeny are released from the sources and disperse while emitting high-energy alpha particles in an effort to destroy the tumor. Since alpha-emitting atoms only diffuse over a short distance, Alpha DaRT aims to primarily affect the tumor and spare the surrounding healthy tissue.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli medical device company focused on the research, development and potential commercialization of Alpha DaRT for the treatment of solid tumors. The technology was originally developed by Prof. Itzhak Kelson and Prof. yona keisari of Tel Aviv University.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. continue”, and similar expressions are intended to identify forward-looking statements. Further, any statement or information that refers to expectations, beliefs, plans, projections, goals, performance, or other characterizations of future events or circumstances, including any underlying assumptions, is forward-looking. . All forward-looking statements are based on Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize his expectations and his beliefs may not turn out to be correct. Actual results could differ materially from those described or implied by these forward-looking statements due to a variety of important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future product or product candidates; (ii) Alpha Tau’s limited operating history; (iii) the significant losses suffered by Alpha Tau to date; (iv) Alpha Tau’s need for additional funding and its ability to raise capital when needed; (v) Alpha Tau’s limited experience in the discovery and development of medical devices; (vi) Alpha Tau’s dependence on the success and commercialization of Alpha DaRT technology; (vii) the inability of preliminary data from clinical studies of Alpha Tau to predict the final results of the study; (viii) the failure of early clinical studies or preclinical studies of Alpha Tau to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) adverse side effects caused by Alpha Tau’s Alpha DaRT technology or any future product or product candidate; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with numerous regulations applicable to it; (xiii) ability to meet Nasdaq listing standards; (xiv) costs associated with being a public company; (xv) changes in applicable laws or regulations; (xix) impacts of the COVID-19 pandemic; and other important factors discussed under “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 28, 2022, and other filings Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These forward-looking statements represent management’s estimates as of the date of this press release. Whereas Alpha-Tau may choose to update these forward-looking statements at some time in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events change its views. These forward-looking statements should not be taken to represent the views of Alpha Tau as of any date subsequent to the date of this press release.

Investor Relations
[email protected]

Logo- https://mma.prnewswire.com/media/733268/Alpha_Tau_Medical_Logo.jpg

SOURCE Alpha Tau Medical

]]>
The Jewish General Hospital inaugurates a research laboratory on cancer treatment using magnetodrones https://parentraide-cancer.org/the-jewish-general-hospital-inaugurates-a-research-laboratory-on-cancer-treatment-using-magnetodrones/ Mon, 20 Jun 2022 22:14:00 +0000 https://parentraide-cancer.org/the-jewish-general-hospital-inaugurates-a-research-laboratory-on-cancer-treatment-using-magnetodrones/ “The Starpax project fits perfectly into the overall strategy of the CIUSSS du Centre-Ouest de Montréal to place increasing emphasis on the use and active development of new forms of technology to meet the needs of patients” , said Dr. Lawrence Rosenberg, President and CEO of the CIUSSS. “With the help of the government and […]]]>

“The Starpax project fits perfectly into the overall strategy of the CIUSSS du Centre-Ouest de Montréal to place increasing emphasis on the use and active development of new forms of technology to meet the needs of patients” , said Dr. Lawrence Rosenberg, President and CEO of the CIUSSS. “With the help of the government and our partners, we intend to apply all our world-renowned expertise to reduce the burden of cancer and its treatment.”

Starpax Biopharma Inc. has developed a novel 3D precision magnetodrone guidance therapy in tumors. Magnetodrones are unique drug-carrying bacteria developed by Starpax that are sensitive to magnetic fields. They deliver the drug into the tumor mass, without allowing the drug to travel through the bloodstream. At the same time, magnetodrones saturate hypoxic areas where cancer cells are difficult to reach with other treatments. The magnetodrones are injected directly into the tumor and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak prevents the magnetdrones from leaving the tumor and guides them in 3D with special magnetic fields.

“Starpax is thrilled to unveil this world first, the invention of precision magnetodrone guidance therapy with the PolarTrak,” said Michael Gareau, Founding President of Starpax Biopharma. “This unprecedented multidisciplinary technology, with preclinical results demonstrating a 100% remission rate with no observed side effects, brings together 31 inventions in four scientific disciplines, including microbiology, biochemistry, electromagnetics and artificial intelligence. It propels cancer medicine into the future. “

“We are committed to bringing this innovation to our patients here, but also eventually to patients around the world,” notes Dr. Gerald Batiste, oncologist and director of the Segal Cancer Center at the JGH. “Such an approach has enormous potential and could help us better treat many types of cancer. Innovation requires building bridges and then crossing them, as well as sharing knowledge, resources and vision to create new hope and better results.

This new approach has the potential to reduce the toxicity of treatments compared to current systemic use, resulting in long-term cost savings to the healthcare system.

The Ministry of Economy and Innovation has granted funding of up to $7 million to set up the PolarTrak room. This financing will cover 80% of the cost of renovating and equipping the hall. The JGH Foundation contributed 20% of the funding for this project.

“If we want to have an efficient and effective health system, we must equip our specialists with state-of-the-art equipment,” said Peter Fitzgibbon, Minister of Economy and Innovation and Minister responsible for Regional Economic Development. “This new room at the Jewish General Hospital will make it possible to innovate with cutting-edge treatments, in addition to creating direct spinoffs from the dynamism of research in Quebec. This is exactly the type of project that makes our science industry shine here and around the world.”

The first clinical studies in humans will focus on six types of cancer: metastases to the pancreas, prostate, head and neck, rectum, vulva and skin, including recurrence of breast cancer.

“Polytechnique is proud to have been at the genesis of the scientific advances that led to the development of this very promising new way to treat cancer,” said Gilles Savard, interim director general of Polytechnique Montréal. “This is a fine example of university research, where multiple collaborations, including those of Starpax and the Jewish General Hospital, are paving the way for applications that have a direct and positive impact on society.

The first human clinical trials are expected to begin in late 2022 or early 2023.

SOURCE Starpax Biopharma

Information: For more details and interview requests: For the CIUSSS: [email protected]; For Starpax: [email protected]; For Minister Fitzgibbon: [email protected]

]]>
This hybrid sensor can help with cancer detection, monitoring and treatment response https://parentraide-cancer.org/this-hybrid-sensor-can-help-with-cancer-detection-monitoring-and-treatment-response/ Sun, 19 Jun 2022 05:21:44 +0000 https://parentraide-cancer.org/this-hybrid-sensor-can-help-with-cancer-detection-monitoring-and-treatment-response/ A “lab-on-a-chip” is a miniature sensor device capable of performing complex biochemical analysis that is considered one of the most promising approaches for the early detection of cancer. Photo: iStock Moscow: A team of researchers has developed a nanophotonic-microfluidic sensor whose potential applications include cancer detection, monitoring and evaluation of response to treatment. The study, […]]]>

A “lab-on-a-chip” is a miniature sensor device capable of performing complex biochemical analysis that is considered one of the most promising approaches for the early detection of cancer.

Photo: iStock

Moscow: A team of researchers has developed a nanophotonic-microfluidic sensor whose potential applications include cancer detection, monitoring and evaluation of response to treatment.
The study, published in the journal Optics Letters, says the device can identify dissolved gases and liquids at low concentrations with a high degree of accuracy.
A ‘lab on a chip‘ is a miniature sensor capable of performing complex biochemical analysis that is considered to be one of the most promising approaches for the early detection of cancer.

Russian researchers have developed a new nanophotonic-microfluidic hybrid sensor for the highly sensitive analysis of liquids and gases at very low concentrations in solutions.

“Our study is an important step towards creating a compact lab-on-a-chip device capable of not only performing a comprehensive set of blood tests, but also detecting cancer biomarkers at an early stage using a very small amount. of the patient’s blood,” said researcher Gregory Goltsman of HSE Moscow University.

The current device consists of nanophotonic optical sensors on a chip in combination with microfluidic channels above the sensor surface.

Fluids or gases pumped through the channels affect the propagation of optical radiation in highly sensitive nanophotonic devices, changing the spectral characteristics of the output.

By examining these changes, researchers can determine the composition of the sample.

A special feature of the device is the small size of the microfluidic channels that deliver the samples to the sensors.

This allows results to be obtained even from very small samples, which can be critical when on-site analysis is not possible and samples must be transported elsewhere for examination.

]]>
Woman needs 10 million naira for breast cancer treatment – ​​The Sun Nigeria https://parentraide-cancer.org/woman-needs-10-million-naira-for-breast-cancer-treatment-the-sun-nigeria/ Thu, 16 Jun 2022 23:07:53 +0000 https://parentraide-cancer.org/woman-needs-10-million-naira-for-breast-cancer-treatment-the-sun-nigeria/ By Jobs Osazuwa Mrs. Nwakaego Ashinze is in dire need of 10 million naira to fight breast cancer which has shaken her, making life almost meaningless for the poor woman. The 42-year-old was recently diagnosed with breast cancer at Eko Hospital in Lagos. Are you a 40+ male? Don’t miss Vital Information, it leaves in […]]]>

By Jobs Osazuwa

Mrs. Nwakaego Ashinze is in dire need of 10 million naira to fight breast cancer which has shaken her, making life almost meaningless for the poor woman.

The 42-year-old was recently diagnosed with breast cancer at Eko Hospital in Lagos.

Are you a 40+ male? Don’t miss Vital Information, it leaves in 2 days! CLICK HERE to READ .

A statement from the hospital says she is also at the crucial stage as cancer cells are rapidly spreading to other parts of her body.

As collected, unless something is urgently done to save her, the worst could happen.

In a letter dated May 22 and signed by consultant oncologist Prof Popoola, the doctors said: “Ashinze is being treated at our facility for left breast cancer. She was seen by the oncologist on May 12. Chest CT scan report showed generalized lung and axial cancer.

“She was then placed on targeted therapy which will last for a year (three weeks apart) after completing eight courses of chemotherapy here.

“Each course of this targeted therapy costs N800,000 and will be taken 12 times. The patient can no longer afford the cost of the therapy.

“Please give him the necessary support.”

The total cost of his treatment is set at N10 million.

Ms. Ashinze is from Ubulu-Uku in the Aniocha South Local Council area of ​​Delta State.

Meanwhile, through an online fundraising campaign launched by Mr Sunday Odiaka, a cousin of Ms Ashinze and a media professional based in Awka, Anambra State, the sum of N400,000 has been collected and sent for processing.

However, she appeals to kind-hearted Nigerians to help her so that she can live a vivacious life again.

She can be contacted through her husband, 07032612663, or Sunday Odiaka, 0703 430 3174. Any financial assistance can be provided to her through Keystone Bank, 6012271010, Ashinze Nwakaego.

Partner with me, let you make N500K to N500K per month! Skills open doors to financial opportunities Click here to learn it .

]]>
Combination of three technologies makes potential treatment effective against aggressive brain tumors https://parentraide-cancer.org/combination-of-three-technologies-makes-potential-treatment-effective-against-aggressive-brain-tumors/ Wed, 15 Jun 2022 05:12:00 +0000 https://parentraide-cancer.org/combination-of-three-technologies-makes-potential-treatment-effective-against-aggressive-brain-tumors/ A drug carrier capable of reaching the brain, attaching to an aggressive type of tumor called glioblastoma multiforme and releasing a chemotherapeutic agent has been tested for the first time by Brazilian researchers. According to an article published in the International Journal of Pharmacythe potential treatment has been shown to be effective in isolated cells […]]]>

A drug carrier capable of reaching the brain, attaching to an aggressive type of tumor called glioblastoma multiforme and releasing a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

According to an article published in the International Journal of Pharmacythe potential treatment has been shown to be effective in isolated cells and animal models through a combination of nanotechnology, chemotherapy and a monoclonal antibody.

Glioblastoma multiforme accounts for 60% of all brain tumors in adults and is also the most aggressive type of brain cancer. Even after surgery, radiotherapy and conventional chemotherapy, patient survival averages about 14 months. One of the reasons is angiogenesis, a process by which the tumor rapidly creates its own blood vessels in order to grow.

Another difficulty is the blood-brain barrier, which prevents drugs from reaching the tumor.”


Leonardo Di Filippo, PhD student and researcher, Araraquara School of Pharmaceutical Sciences, São Paulo State University

To address these challenges, Di Filippo worked with fellow researchers from UNESP and two other Brazilian institutions, the University of Campinas (UNICAMP) and the University of São Paulo (USP) in Ribeirão Preto, to combine docetaxel , a potent chemotherapeutic agent, with a nanostructured lipid carrier designed to cross the blood-brain barrier. “We developed a formulation in which the substances were stably combined,” he said.

The researchers also paired the transporter with bevacizumab, a monoclonal antibody developed against vascular endothelial growth factor (VEGF) and approved for other uses. “VEGF is the cancer protein that stimulates angiogenesis and tends to be overexpressed in glioblastoma multiforme,” Di Filippo explained. The goal was to create a formulation capable of entering the brain and releasing a chemotherapy drug to destroy the tumor.

“Developing this system with this app is an innovation,” said Marlus Chorili, a UNESP professor and principal investigator of the FAPESP-supported project.

Quality testing

After creating the nanostructured lipid carrier with docetaxel and bevacizumab, the researchers set out to ensure that it met certain basic criteria. Laboratory tests showed its size to be 128 nanometers, small enough to cross the blood-brain barrier. In addition, the entrapment of docetaxel was 90% and the coupling efficiency of bevacizumab was 62%. “These are positive numbers, sufficient to ensure adequate therapeutic concentrations,” Di Filippo said.

The next step was to evaluate the effects of the compound on two glioblastoma cell lines and healthy cells. The nanocarrier eliminated five times more cancer cells than docetaxel alone without affecting healthy cells. It was particularly effective against U87MG, a glioblastoma cell that overexpresses VEGF, but less so against A172, which expresses relatively little VEGF. “These results show that our nanocarrier selectively attacks cells that express a lot of VEGF,” Di Filippo said.

The researchers also found that the potential drug was able to enter cancer cells and release docetaxel continuously for around 84 hours, suggesting prolonged availability of the chemotherapy drug in the body.

Good results in animals

Using techniques developed by the UNICAMP team, rats were inoculated with glioma cells (glioma is a type of cancer similar to glioblastoma). Five days later, they were divided into six groups: treatment with placebo; docetaxel alone; nanocarrier alone, without bevacizumab or docetaxel; nanocarrier and bevacizumab, without docetaxel; nanocarrier and docetaxel, without bevacizumab; nanocarrier with docetaxel and bevacizumab.

After 15 days, the first four groups turned out not to have benefited from the treatment. In the fifth group (nanocarrier with docetaxel) and the sixth group (nanocarrier with docetaxel and bevacizumab), the tumor volume was reduced by 40% and 70% respectively. “These are significant numbers for trials of this type,” Chorilli said.

The researchers also found that the formulation did not cause any deterioration in levels of biomarkers such as albumin and creatinine compared to using docetaxel alone. “It shows that the toxicity has not been intensified,” Di Filippo explained.

Next steps

According to Chorilli, the results were positive but these were the first experiences with the nanostructured lipid carrier for this specific application. “We need to conduct more studies using isolated cells and animals. If the results against glioblastoma multiforme remain good, we could try to find partners for clinical trials with human volunteers,” he said. .

The study reported in the article highlighted the potential of lipid nanocarriers in the treatment of brain cancer, he added: “We can use different combinations with other monoclonal antibodies and chemotherapy drugs against other types of cancer. Many years will undoubtedly be needed to complete this research. .”

Chorilli is studying similar methods for treating infections, such as gastritis and other illnesses caused by the bacteria Helicobacter pyloriin research also supported by FAPESP.

Source:

Journal reference:

DiFilippo, L, D., et al. (2022) Targeted delivery of docetaxel glioblastoma multiforme using bevacizumab-modified nanostructured lipid transporters alters in vitro cell growth and tumor progression in vivo. International Journal of Pharmacy. doi.org/10.1016/j.ijpharm.2022.121682

]]>